Morepen Laboratories Ltd
Morepen Laboratories Ltd (MOREPENLAB) last traded at ₹93.7, a market capitalisation of ₹5,136 crore, on a P/E of 43.8. Over the past 52 weeks the stock has ranged between ₹33 and ₹98.3. Morepen Laboratories Ltd last reported results for the quarter ended Jun 2026, with sales of ₹570 crore and net profit of ₹56 crore. The next scheduled event is a dividend on 19 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.
Morepen Laboratories Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Morepen Laboratories Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹570 cr, up 34.1% from ₹425 cr a year earlier. Net profit was ₹56 cr, up 409.1% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 438 | 453 | 466 | 425 | 412 | 484 | 485 | 570 |
| Expenses | 394 | 417 | 424 | 401 | 381 | 438 | 460 | 488 |
| Operating profit | 44 | 36 | 42 | 24 | 31 | 46 | 24 | 83 |
| OPM % | 10% | 8% | 9% | 6% | 7% | 10% | 5% | 14% |
| Other income | 5 | 5 | 5 | 4 | 30 | 4 | 8 | 5 |
| Interest | 1 | 1 | 5 | 4 | 4 | 4 | 4 | 5 |
| Depreciation | 2 | 5 | 16 | 9 | 11 | 10 | 6 | 8 |
| Profit before tax | 46 | 35 | 26 | 16 | 46 | 35 | 23 | 75 |
| Tax % | 24% | 24% | 21% | 26% | 10% | 22% | 33% | 24% |
| Net profit | 35 | 27 | 20 | 11 | 41 | 28 | 16 | 56 |
| EPS (₹) | 0.64 | 0.49 | 0.37 | 0.20 | 0.75 | 0.50 | 0.29 | 1.03 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Morepen Laboratories Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 1,188 | 1,547 | 1,418 | 1,690 | 1,812 | 1,806 | 1,951 |
| Operating profit | 119 | 137 | 80 | 159 | 174 | 126 | 184 |
| OPM % | 10% | 9% | 6% | 9% | 10% | 7% | 9% |
| Net profit | 97 | 102 | 39 | 97 | 118 | 96 | 141 |
| EPS (₹) | 2.16 | 2.13 | 0.76 | 1.88 | 2.15 | 1.73 | 2.57 |
TTM is the trailing twelve months to the most recent quarter.
Morepen Laboratories Ltd growth and returns
- 10 Years
- 14%
- 5 Years
- 9%
- 3 Years
- 8%
- TTM
- 9%
- 10 Years
- 16%
- 5 Years
- -5%
- 3 Years
- 24%
- TTM
- 27%
- 10 Years
- 17%
- 5 Years
- 13%
- 3 Years
- 36%
- 1 Year
- 97%
- 10 Years
- 12%
- 5 Years
- 10%
- 3 Years
- 10%
- Last Year
- 6%
Morepen Laboratories Ltd shareholding pattern
Promoters held 35.66% at Jun 2026, broadly unchanged since Jun 2025. FIIs 1.46% and DIIs 1.28%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 35.66% | 35.66% | 35.66% | 35.66% | 35.66% | 35.66% | 35.66% | 35.66% |
| FIIs | 2.08% | 2.22% | 1.94% | 1.72% | 1.62% | 1.62% | 1.59% | 1.46% |
| DIIs | 1.69% | 1.64% | 1.67% | 1.50% | 1.49% | 1.25% | 1.25% | 1.28% |
| Government | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public | 60.57% | 60.46% | 60.72% | 61.09% | 61.22% | 61.46% | 61.50% | 61.59% |
| No. of shareholders | 4,30,929 | 4,48,361 | 4,68,860 | 4,61,180 | 4,61,853 | 4,53,137 | 4,47,286 | 4,34,912 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Morepen Laboratories Ltd events
The next scheduled event is a dividend on 19 Sept 2026.
- DividendRecord date for final dividend for FY ended March 31, 2026, subject to AGM approval
- AGM41st Annual General Meeting to approve final dividend, hiving off Medical Devices Business, and re-appointment of Chairman & MD.
See the full results calendar for every Indian company reporting in the next 30 days.
Morepen Laboratories Ltd corporate filings
- Allotment of equity shares by Morepen RX Limited, wholly owned subsidiary of the companyCompany Updatelow impact
Cruxal's analysis: Morepen Laboratories Limited has subscribed to a rights issue of its wholly owned…
Read the full analysis - Newspaper Publication Financial Results for the quarter ended June 30, 2026Company Updatehigh impact
Cruxal's analysis: Morepen Laboratories Limited has reported robust financial results for the quarter ended…
Read the full analysis - Announcement under Regulation 30 (LODR)-Monitoring Agency ReportCompany Updatelow impact
Cruxal's analysis: Morepen Laboratories Ltd has submitted its monitoring agency report for the quarter ended…
Read the full analysis - 41st Annual General Meeting scheduled to be held on September 26, 2026Company Updatelow impact
Cruxal's analysis: Morepen Laboratories Ltd (500288) has formally intimated that its 41st Annual General…
Read the full analysis - Re-appointment of Mr. Sushil Suri as Chairman & Managing Director w.e.f. October 20, 2026Company Updatehigh impact
Cruxal's analysis: Morepen Laboratories Limited announced exceptionally strong consolidated financial…
Read the full analysis - Intimation Of Record Date For Payment Of Final Dividend I.E. September 19, 2026Corp. Actionmedium impact
- Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseCompany Updatelow impact
Cruxal's analysis: Morepen Laboratories Ltd. announced on 2026-08-04 that it has filed a press release/media…
Read the full analysis - Announcement under Regulation 30 (LODR)-Investor PresentationCompany Updatehigh impact
Cruxal's analysis: Morepen Laboratories Limited has announced an exceptionally strong Q1 FY27, reporting its…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Morepen Laboratories Ltd
Cruxal reads every Morepen Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.